Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical

Early Stage

Own a stake for health equality; affordable and accessible for all

Own a stake for health equality; affordable and accessible for all

Overview

Funding data not publicly available
Platform

Self Managed

Start Date

04/24/2023

Close Date

Not Provided

Min. Goal
$10,000,000
Max. Goal
$10,000,000
Min. Investment

$0

Security Type

Convertible Note

Series

Series A

SEC Filing Type

RegD 506(c)    Open SEC Filing

Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Location

Huntington, New York

Sen-Jam Pharmaceutical, with a valuation of $70 million, is raising funds on Dealmaker Securities with a Reg D 506(c) raise. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $10 million. The campaign proceeds will be used to advance the different phases of its clinical trials.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Sen-Jam Pharmaceutical 09/14/2024 Wefunder $80,000,000 $1,314,628 Convertible Note Active RegCF
Sen-Jam Pharmaceutical 01/05/2024 Self Managed - - Convertible Note Funded RegD 506(c)
Sen-Jam Pharmaceutical 01/10/2023 StartEngine $69,979,019 $312,093 Equity - Common Funded RegCF
Sen-Jam Pharmaceutical 07/30/2022 Wefunder $25,000,000 $1,008,951 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Add to portfolio
Sen-Jam Pharmaceutical on Dealmaker Securities 2023
Platform: Self Managed
Security Type: Convertible Note

Follow company

Follow Sen-Jam Pharmaceutical on Dealmaker Securities 2023

Buy Sen-Jam Pharmaceutical's Deal Report

Warning: according to the close date for this deal, Sen-Jam Pharmaceutical may no longer be accepting investments.

Sen-Jam Pharmaceutical Deal Report

Get KingsCrowd’s comprehensive report on Sen-Jam Pharmaceutical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sen-Jam Pharmaceutical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sen-Jam Pharmaceutical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge